Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar;51(1):58-60.
doi: 10.4997/JRCPE.2021.114.

Levetiracetam-induced systemic lupus erythematosus

Affiliations
Case Reports

Levetiracetam-induced systemic lupus erythematosus

Praveen Jadhav et al. J R Coll Physicians Edinb. 2021 Mar.

Abstract

Systemic lupus erythematosus (SLE) is a rare autoimmune disorder in a physician's practice, commonly presenting in young females. It is rare for SLE to present at a late age. Though SLE is idiopathic, sometimes it can present as an adverse reaction to drugs. Quite a few drugs are implicated in this process. However, there are no reports of levetiracetam causing SLE. Here, we present a case of 62-year-old female presenting with SLE after consumption of levetiracetam for 1 year for her epilepsy. Erythematosus rash was her main symptom. This was associated with a strong positivity of antinuclear antibody. The symptoms remitted completely after the discontinuation of levetiracetam, suggesting them to be because of drug-induced lupus (DIL). DIL differs from SLE in being mild, affecting atypical age groups and resolving completely on withdrawal of the drug.

Keywords: adverse drug reaction; antiepileptic; drug-induced lupus; levetiracetam; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

No conflict of interests declared

Publication types

LinkOut - more resources